← All Cordyceps Sunshine Biotech Holdings Co, LTD filings

Cordyceps Sunshine Biotech Holdings Co, LTD 20-F annual reports

The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.

OQB
RAJAF
Cordyceps Sunshine Biotech Holdings Co, LTD
20-F/A: Cordyceps Sunshine Biotech Restates 2023 Results, Shifts Focus
Cordyceps Sunshine Biotech Holdings Co., Ltd. filed an amended annual report for 2023, restating financial results and detailing a strategic spin-off of its Cordyceps business to focus on Cattle camphor mushroom products.
OQB
RAJAF
Cordyceps Sunshine Biotech Holdings Co, LTD
20-F: Cordyceps Sunshine Biotech Reports 2024 Loss Amid Strategic Pivot to Taiwanofungus and Internal Control Weaknesses
Cordyceps Sunshine Biotech Holdings Co., Ltd. reported a net loss of $226,258 for fiscal year 2024, driven by increased operating expenses and depreciation, as it pivots its core business entirely to Cattle camphor mushroom products following the spin-off of its Cordyceps operations.
OQB
RAJAF
Cordyceps Sunshine Biotech Holdings Co, LTD
20-F/A: Cordyceps Sunshine Biotech Amends 20-F Filing to Clarify China-Specific Disclosures and Operational Results
Cordyceps Sunshine Biotech amends its annual report on Form 20-F to provide additional disclosure regarding SEC staff comments on China-based companies and to clarify operational results for 2021-2023.
OQB
RAJAF
Cordyceps Sunshine Biotech Holdings Co, LTD
20-F: Cordyceps Sunshine Biotech Holdings Co. Ltd. Files 20-F Annual Report, Details Patent Licensing and Financial Performance
Cordyceps Sunshine Biotech Holdings Co., Ltd. files its 20-F annual report, outlining a patent exclusive license agreement, financial results, and risk factors.